page_banner

Products

Roflumilast CAS:162401-32-3

Short Description:

Catalog Number: XD96297
Cas: 162401-32-3
Molecular Formula: C17H14Cl2F2N2O3
Molecular Weight: 403.21
Availability: In Stock 
Price:  
Prepack:  
Bulk Pack: Request Quote

 


Product Detail

Product Tags

Catalog Number XD96297
Product Name Roflumilast
CAS 162401-32-3
Molecular Formula C17H14Cl2F2N2O3
Molecular Weight 403.21
Storage Details Ambient

 

Product Specification

Appearance White powder
Assay 99% min

 

Roflumilast is a medication primarily used for the treatment of chronic obstructive pulmonary disease (COPD) in patients with severe symptoms.One of the main effects of Roflumilast is its ability to reduce inflammation in the airways. In COPD, inflammation plays a significant role in narrowing the airways and causing symptoms such as cough, shortness of breath, and wheezing. Roflumilast works by inhibiting an enzyme called phosphodiesterase-4 (PDE4), which is involved in the inflammatory response. By inhibiting PDE4, Roflumilast decreases the production of inflammatory mediators, thus reducing airway inflammation and improving lung function.In addition to its anti-inflammatory effects, Roflumilast also has some bronchodilatory properties, meaning it can help relax the muscles in the airways and improve airflow. However, it is important to note that Roflumilast is not a fast-acting bronchodilator like short-acting beta-agonists and should not be used for immediate relief of acute COPD symptoms.Roflumilast has been shown to reduce exacerbations (flare-ups) in patients with severe COPD. Exacerbations can be triggered by various factors, including respiratory infections and exposure to pollutants. These episodes can cause a rapid worsening of symptoms and may require hospitalization. By reducing inflammation and suppressing the release of inflammatory mediators, Roflumilast can help prevent exacerbations and improve overall disease control.Furthermore, Roflumilast has been studied for its potential effects on lung function and exercise tolerance in COPD patients. Research has shown that treatment with Roflumilast can lead to improvements in lung function as measured by forced expiratory volume in one second (FEV1). It has also been associated with increased exercise capacity, allowing patients to engage in physical activities more comfortably.However, it is important to note that Roflumilast is not suitable for everyone and can have side effects, including diarrhea, nausea, headache, and weight loss. It may also interact with other medications, so it is important to consult a healthcare professional before starting Roflumilast.In summary, Roflumilast is a medication used for the treatment of severe COPD. It works by reducing airway inflammation, improving lung function, and preventing exacerbations. While it has shown promise in managing COPD symptoms, it is important to discuss with a healthcare professional to determine if Roflumilast is the right treatment option and to monitor for any potential side effects.


  • Previous:
  • Next:

  • Close

    Roflumilast CAS:162401-32-3